ALS Biologics
Cell‑therapy company leveraging ALScell™ to treat ALS and related neurodegenerative diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Cell‑therapy company leveraging ALScell™ to treat ALS and related neurodegenerative diseases.
NeurologyNeurodegeneration
Technology Platform
ALScell™ (JadiCell™) is a proprietary MSC‑like cell line engineered for amplified growth‑factor, exosome, angiogenic and neurogenic output, providing multi‑modal neuroprotection and regeneration.
Opportunities
Successful early‑phase data could unlock partnerships with major neuro‑pharma firms and enable expansion into other neurodegenerative and injury indications.
Risk Factors
Manufacturing scalability, regulatory approval pathways, and competition from alternative cell‑ and and gene‑therapy ALS candidates pose significant risks.
Competitive Landscape
ALS Biologics differentiates itself through the ALScell™ platform’s enhanced secretome, but competes with other MSC‑based therapies and emerging gene‑editing approaches targeting ALS.